Details of the Drug

General Information of Drug (ID: DM25CGV)

Drug Name
Selenium
Synonyms
Selenium; Selenium alloy; Selenium and compounds; Selenium anhydride; Selenium base; Selenium dihydride; Selenium dust; Selenium elemental; Selenium homopolymer; Selenium hydride; Selenium metallicum; Selenium, colloidal; Selenium, elemental; Selenium, metallic; Vandex; selenio; 7782-49-2; CCRIS 4250; Caswell No. 732; EINECS 231-957-4; Colloidal selenium; Electronic E-2; Elemental selenium; Gray selenium; Hydrogen selenide (H2Se); SELENIUM ATOM; SELENIUM COMPOUNDS; SELENIUM POWDER; Selen [Polish]; HSDB 4493; Se; Selen; UNII-H6241UJ22B
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 78.97
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 0
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 9.17 h [1]
Bioavailability
The bioavailability of drug is 90% [1]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.7 days [1]
Metabolism
The drug is metabolized via the glutathione reductase enzymes or reduction by thioredoxin reductases [2]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Blood and lymphatic system disorders Not Available THBD OT8VHLKY [3]
Blood and lymphatic system disorders Not Available VWF OTNMMA2P [3]
Chemical Identifiers
Formula
Se
IUPAC Name
selenium
Canonical SMILES
[Se]
InChI
BUGBHKTXTAQXES-UHFFFAOYSA-N
InChIKey
1S/Se
Cross-matching ID
PubChem CID
6326970
ChEBI ID
CHEBI:27568
CAS Number
7782-49-2
DrugBank ID
DB11135
INTEDE ID
DR1469

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Thioredoxin reductase TR1 (TXNRD1) DEUP4DA TRXR1_HUMAN Substrate [4]
Glutathione reductase (GSR) DEGDPL2 GSHR_HUMAN Substrate [4]
Selenocysteine lyase (SCLY) DEH4TD6 SCLY_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
(3R)-3-hydroxyacyl-CoA dehydrogenase (HSD17B8) OTX1DWEF DHB8_HUMAN Gene/Protein Processing [5]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) OT5I4Y9K PLCB_HUMAN Gene/Protein Processing [5]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4) OTPA0QHW PLCB4_HUMAN Gene/Protein Processing [5]
14-3-3 protein epsilon OT3WQXNA 1433E_HUMAN Gene/Protein Processing [5]
18S rRNA aminocarboxypropyltransferase (TSR3) OTR3RQ6I TSR3_HUMAN Gene/Protein Processing [5]
2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial (GCAT) OT6WZPWV KBL_HUMAN Gene/Protein Processing [5]
26S proteasome complex subunit SEM1 (SEM1) OTASLBM1 SEM1_HUMAN Gene/Protein Processing [5]
26S proteasome non-ATPase regulatory subunit 4 (PSMD4) OTH1VZTM PSMD4_HUMAN Gene/Protein Processing [5]
26S proteasome non-ATPase regulatory subunit 6 (PSMD6) OTX59EGK PSMD6_HUMAN Gene/Protein Processing [5]
26S proteasome non-ATPase regulatory subunit 8 (PSMD8) OTY6X27P PSMD8_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Absorption, excretion, and retention of selenium from a high selenium yeast in men with a high intake of selenium. Food Nutr Res. 2008;52. doi: 10.3402/fnr.v52i0.1642. Epub 2008 Feb 12.
2 Sun H, Frassetto LA, Huang Y, Benet LZ: Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther. 2010 Apr;87(4):465-72. doi: 10.1038/clpt.2009.247. Epub 2010 Jan 20.
3 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
4 Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999 Sep;20(9):1657-66.
5 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.